To learn more about the future of precision medicine we reached out to one of the foundational companies in genomic diagnostics—Illumina. Next Generation Sequencing (NGS), a high-throughput technology that rapidly deciphers large sections of DNA or RNA with unprecedented accuracy, is at the heart of precision diagnostics today. In its scaling and commercialization, Illumina played a pivotal role. The company’s CEO, Jacob Thaysen, shares his excitement about moving beyond pure genomics analysis—into multiomics: ‘Multiomics represents the integration of various biological data types, such as genomics, transcriptomics, epigenomics, and proteomics, to provide a deeper understanding of biology. While genomics remains the foundation, we have learned that genomic data alone is often insufficient to fully understand biological systems.’ Thaysen explains that the advent of AI has enabled the industry to venture into much more complex analysis. ‘With the ability to analyze genomic, RNA, epigenetic, and proteomic data on a single platform, we are entering a transformative era,’ he says, adding: ‘Over the next decade, this integration will redefine how healthcare systems, researchers, and the pharmaceutical industry approach biology and medicine.’